The Greater Cannabis Company, Inc
Advertisement
The Greater Cannabis Company, Inc. is a Baltimore-based organization dedicated to developing transformative therapeutics for neuropsychiatric disorders, with a particular focus on autism spectrum disorders (ASD). Their subsidiary, GCANRx, is advancing innovative pharmaceutical-grade treatments aimed at addressing the core symptoms of these conditions while minimizing the side effects commonly associated with existing medications.
With the recent approval of a Phase 2 clinical trial by the Israeli Ministry of Health, GCANRx aims to explore the safety and efficacy of their neuroprotective cannabinoid therapeutic. The company addresses a significant unmet need, as ASD currently affects over 5 million children in the U.S., resulting in substantial economic costs and a demand for more effective treatment options.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.
Advertisement